Latest Ablynx Stories
DUBLIN, March 5, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/885sfr/bispecific ) has announced the addition of the "Concise Analysis
Adrenaline, the hormone that prepares our body to fight or flight, acts on a hyperdynamic receptor.
Symposium will Present the Latest Research in Biopharmaceutical Drug Discovery DANBURY, Conn., March 25 /PRNewswire-USNewswire/ -- The Society for Biomolecular Sciences (SBS) will present Biopharmaceuticals: Exploring Synergies Across Drug Formats at the San Francisco Hilton Union Square in San Francisco on May 20-21, 2010.
RALEIGH, N.C., Oct.
Ablynx, a biopharmaceutical company focused on the discovery and development of nanobodies, has received a grant worth E1.8 million from the Institute for the Promotion of Innovation by Science and Technology in Flanders.
The head of biotech research GlaxoSmithKline Plc said a new generation of "slimline" antibody medicines may be successors to current blockbusters such as Avastin and Rituxan.
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has entered into an agreement with Ablynx, to co-discover and co-develop Nanobodies against two targets in oncology and immunology. The agreement includes an upfront cash payment to Ablynx of E10 million.
Ablynx and Merck Serono to equally contribute to discover and develop Nanobodies(R) against two targets in oncology and immunology and equally share the resulting profits Ghent, BELGIUM, 4 September 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies(R), a novel class of antibody-derived therapeutic proteins, today announced that it has entered into an agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, to...
- A transitional zone between two communities containing the characteristic species of each.